drugset / Trial / NCT02285920
Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial
Phase 2
Completed
129 enrolled
University of Pennsylvania
Brigham and Women's Hospital · collabGeorge Washington University · collabUniversity of Washington · collabVanderbilt University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The SPin-D Trial is a phase II randomized, double-blind, placebo-controlled, multi-center study of spironolactone (SPL) for patients with hemodialysis-dependent end-stage renal disease.
Timeline
- Start
- 2014-11
- Primary completion
- 2017-06
- Completion
- 2017-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Spironolactone | Small molecule | 12.5 mg | — |
| Comparator | Spironolactone | Small molecule | 25 mg | — |
| Comparator | Spironolactone | Small molecule | 50 mg | — |